BRIEF-ImmunityBio Advances First Line BCG Naive NMIBC Program For Anktiva Plus BCG

Reuters01-16

Jan 16 (Reuters) - Immunitybio Inc IBRX.O:

IMMUNITYBIO ADVANCES FIRST-LINE BCG NAIVE NMIBC PROGRAM WITH ENROLLMENT EXCEEDING EXPECTATIONS AND POSITIVE INTERIM ANALYSIS FOR ANKTIVA® PLUS BCG
IMMUNITYBIO INC: EXPANDED ACCESS PROGRAM (EAP) OF RECOMBINANT BCG PROCEEDING WELL
IMMUNITYBIO : INTERIM ANALYSIS REQUESTED BY FDA DEMONSTRATED STATISTICALLY SIGNIFICANT LONGER DURATION OF COMPLETE RESPONSE WITH ANKTIVA + BCG
IMMUNITYBIO INC: ANTICIPATES SUBMITTING BLA TO U.S. FDA BY YEAR END 2026 FOR ANKTIVA PLUS BCG
IMMUNITYBIO INC - REQUESTS FDA CONSULTATION ON RECOMBINANT BCG USE

Source text: ID:nBw1wnjWQa

Further company coverage: IBRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603993068?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603993068","market":"nz","top_or_hot":-1,"title":"BRIEF-ImmunityBio Advances First Line BCG Naive NMIBC Program For Anktiva Plus BCG","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-ImmunityBio Advances First Line BCG Naive NMIBC Program For Anktiva Plus BCG</title></head><body><p><span>Jan 16 (Reuters)</span><span> - </span>Immunitybio Inc <span>IBRX.O</span>:</p><ul><li><p>IMMUNITYBIO ADVANCES FIRST-LINE BCG NAIVE NMIBC PROGRAM WITH ENROLLMENT EXCEEDING EXPECTATIONS AND POSITIVE INTERIM ANALYSIS FOR ANKTIVA® PLUS BCG</p></li><li><p>IMMUNITYBIO INC: EXPANDED ACCESS PROGRAM (EAP) OF RECOMBINANT BCG PROCEEDING WELL</p></li><li><p>IMMUNITYBIO : INTERIM ANALYSIS REQUESTED BY FDA DEMONSTRATED STATISTICALLY SIGNIFICANT LONGER DURATION OF COMPLETE RESPONSE WITH ANKTIVA + BCG</p></li><li><p>IMMUNITYBIO INC: ANTICIPATES SUBMITTING BLA TO U.S. FDA BY YEAR END 2026 FOR ANKTIVA PLUS BCG</p></li><li><p>IMMUNITYBIO INC - REQUESTS FDA CONSULTATION ON RECOMBINANT BCG USE</p></li></ul><p>Source text: <span>ID:nBw1wnjWQa</span></p><p>Further company coverage: <span>IBRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-ImmunityBio Advances First Line BCG Naive NMIBC Program For Anktiva Plus BCG</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-ImmunityBio Advances First Line BCG Naive NMIBC Program For Anktiva Plus BCG\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-16 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-ImmunityBio Advances First Line BCG Naive NMIBC Program For Anktiva Plus BCG</title></head><body><p><span>Jan 16 (Reuters)</span><span> - </span>Immunitybio Inc <span>IBRX.O</span>:</p><ul><li><p>IMMUNITYBIO ADVANCES FIRST-LINE BCG NAIVE NMIBC PROGRAM WITH ENROLLMENT EXCEEDING EXPECTATIONS AND POSITIVE INTERIM ANALYSIS FOR ANKTIVA® PLUS BCG</p></li><li><p>IMMUNITYBIO INC: EXPANDED ACCESS PROGRAM (EAP) OF RECOMBINANT BCG PROCEEDING WELL</p></li><li><p>IMMUNITYBIO : INTERIM ANALYSIS REQUESTED BY FDA DEMONSTRATED STATISTICALLY SIGNIFICANT LONGER DURATION OF COMPLETE RESPONSE WITH ANKTIVA + BCG</p></li><li><p>IMMUNITYBIO INC: ANTICIPATES SUBMITTING BLA TO U.S. FDA BY YEAR END 2026 FOR ANKTIVA PLUS BCG</p></li><li><p>IMMUNITYBIO INC - REQUESTS FDA CONSULTATION ON RECOMBINANT BCG USE</p></li></ul><p>Source text: <span>ID:nBw1wnjWQa</span></p><p>Further company coverage: <span>IBRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nFWN3YG1LU:1","article_id":"2603993068","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603993068","pubTimestamp":1768566748,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-ImmunityBio Advances First Line BCG Naive NMIBC Program For Anktiva Plus BCGJan 16 (Reuters) - Immunitybio Inc IBRX.O:IMMUNITYBIO ADVANCES FIRST-LINE BCG NAIVE NMIBC PROGRAM WITH ENROLLMENT EXCE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"简介-ImmunityBio推进Anktiva加BCG的一线BCG幼稚NMIBC计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"BRIEF-ImmunityBio Advances First Line BCG Naive NMIBC Program For Anktiva Plus BCGJan 16 (Reuters) - Immunitybio Inc IBRX.O:IMMUNITYBIO ADVANCES FIRST-LINE BCG NAIVE NMIBC PROGRAM WITH ENROLLMENT EXCEEDING EXPECTATIONS AND POSITIVE INTERIM ANALYSIS FOR ANKTIVA® PLUS BCGIMMUNITYBIO INC: EXPANDED ACCESS PROGRAM (EAP) OF RECOMBINANT BCG PROCEEDING WELLIMMUNITYBIO : INTERIM ANALYSIS REQUESTED BY FDA DEMONSTRATED STATISTICALLY SIGNIFICANT LONGER DURATION OF COMPLETE RESPONSE WITH ANKTIVA + BCGIMMUNITYBIO INC: ANTICIPATES SUBMITTING BLA TO U.S. FDA BY YEAR END 2026 FOR ANKTIVA PLUS BCGIMMUNITYBIO INC - REQUESTS FDA CONSULTATION ON RECOMBINANT BCG USESource text: ID:nBw1wnjWQaFurther company coverage: IBRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603993068","isCrawlerRequest":true}